Top

Published in:

01-10-2013 | Research Paper

eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation

Authors: Chao Xu, Duan-min Hu, Qi Zhu

Published in: Clinical & Experimental Metastasis | Issue 7/2013

Abstract

eEF1A2 is a protein translation factor involved in protein synthesis that is overexpressed in various cancers, with important functions in tumor genesis and progression. We have previously showed that the ectopic expression of eEF1A2 is correlated with lymph node metastasis and perineural invasion in pancreatic cancer. In this study, we investigated the functional role of eEF1A2 in the regulation of cell migration, invasion, and metastasis in pancreatic cancer. Furthermore, we investigated the potential molecular mechanisms involved. By evaluating the invasive ability of a panel of pancreatic cancer cell lines with different metastatic potentials, eEF1A2 expression in cells was positively associated with their invasive ability. The knockdown of eEF1A2 by siRNA decreased the migration and invasion of PANC-1 cells. By contrast, the ectopic expression of exogenous eEF1A2 significantly promoted the migration and invasion of SW1990 cells. Stable eEF1A2 overexpression in a nude mouse model of peritoneal metastasis likewise dramatically enhanced the intraperitoneal metastatic ability of SW1990 cells. In addition, eEF1A2 overexpression could upregulate MMP-9 expression and activity. A significant positive correlation between the overexpression of both eEF1A2 and MMP-9 was observed in pancreatic cancer tissues. The inhibition of MMP-9 activity reduced the promoting effect of eEF1A2 on cell migration and invasion. Furthermore, eEF1A2-mediated cell migration and invasion, as well as MMP-9 expression and upregulation, were largely dependent on the eEF1A2-induced Akt activation. The findings suggested the potentially important role of eEF1A2 in pancreatic cancer migration, invasion, and metastasis. Thus, the results provide evidence of eEF1A2 as a potential therapeutic target in the treatment of aggressive pancreatic cancer.

Available only for authorised users

Siegel R, Naishadham D, Jemal A et al (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedCrossRef

Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617PubMedCrossRef

Rhim AD, Mirek ET, Aiello NM et al (2012) EMT and dissemination even precede pancreatic tumor formation. Cell 148(1–2):349–361PubMedCrossRef

Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210PubMedCrossRef

Browne GJ, Proud CG (2002) Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269(22):5360–5368PubMedCrossRef

Soares DC, Barlow PN, Newbery HJ et al (2009) Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One 4(7):e6315PubMedCrossRef

Knudsen SM, Frydenberg J, Clark BF et al (1993) Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem 215(3):549–554PubMedCrossRef

Lee S, Francoeur AM, Liu S et al (1992) Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family. J Biol Chem 267(33):24064–24068PubMed

Bektas M, Nurten R, Gurel Z et al (1994) Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton. FEBS Lett 356(1):89–93PubMedCrossRef

10.

Gross SR, Kinzy TG (2005) Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12(9):772–778PubMedCrossRef

11.

Chung CM, Man C, Jin Y et al (2005) Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 43(3):165–174PubMedCrossRef

12.

Shamovsky I, Ivannikov M, Kandel ES et al (2006) RNA-mediated response to heat shock in mammalian cells. Nature 440(7083):556–560PubMedCrossRef

13.

Chang R, Wang E (2007) Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 100(2):267–278PubMedCrossRef

14.

Amiri A, Noei F, Jeganatham S et al (2007) eEF1A2 activates Akt and stimulates Akt-dependent actin remodelling, invasion and migration. Oncogene 26(21):3027–3040PubMedCrossRef

15.

Li Z, Qi CF, Shin DM et al (2010) Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One 5(5):e10755PubMedCrossRef

16.

Anand N, Murthy S, Amann G et al (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31(3):301–305PubMed

17.

Tomlinson VA, Newbery HJ, Wray NR et al (2005) Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 5:113PubMedCrossRef

18.

Li R, Wang H, Bekele BN et al (2006) Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 25(18):2628–2635PubMedCrossRef

19.

Scaggiante B, Dapas B, Bonin S et al (2012) Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression. Br J Cancer 106(1):166–173PubMedCrossRef

20.

Grassi G, Scaggiante B, Farra R et al (2007) The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie 89(12):1544–1552PubMedCrossRef

21.

Cao HX, Zhu Q, Huang J et al (2009) Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun 380(1):11–16PubMedCrossRef

22.

Hu DM, Xu C, Zhu Q (2013) eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma. Hepatogastroenterology 60(124):222–227

23.

Pencil SD, Toh Y, Nicolson GL (1993) Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Res Treat 25(2):165–174PubMedCrossRef

24.

Edmonds BT, Wyckoff J, Yeung YG et al (1996) Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci 109(Pt 11):2705–2714PubMed

25.

Pecorari L, Marin O, Silvestri C et al (2009) Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer 8:58PubMedCrossRef

26.

Li Y, Aoki T, Mori Y et al (2004) Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64(19):7058–7064PubMedCrossRef

27.

Ozaki H, Matsuzaki H, Ando H et al (2012) Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis 29(3):229–238PubMedCrossRef

28.

Pryczynicz A, Guzińska-Ustymowicz K, Dymicka-Piekarska V et al (2007) Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 45(1):37–40PubMed

29.

Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. Essays Biochem 38:21–36PubMed

30.

Bernhard EJ, Gruber SB, Muschel RJ (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91(10):4293–4297PubMedCrossRef

31.

Gress TM, Müller-Pillasch F, Lerch MM et al (1995) Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 62(4):407–413PubMedCrossRef

32.

Shi WD, Meng ZQ, Chen Z et al (2009) Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett 283(1):84–91PubMedCrossRef

33.

Chin YR, Toker A (2009) Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 21(4):470–476PubMedCrossRef

34.

Meng Q, Xia C, Fang J et al (2006) Role of PI3 K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18(12):2262–2271PubMedCrossRef

35.

Grille SJ, Bellacosa A, Upson J et al (2003) The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma line. Cancer Res 63(9):2172–2178PubMed

36.

Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17(1):23–30PubMedCrossRef

37.

Panasyuk G, Nemazanyy I, Filonenko V et al (2008) A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules. Int J Biochem Cell Biol 40(1):63–71PubMedCrossRef

38.

Zhu X, Wang L, Zhang B et al (2011) TGF-beta 1-induced PI3 K/Akt/NF-kappa B/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. J Biochem 149(4):405–414PubMedCrossRef

39.

Kim D, Kim S, Koh H et al (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15(11):1953–1962PubMedCrossRef

Title: eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation
Authors: Chao Xu
Duan-min Hu
Qi Zhu
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-013-9593-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells

Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver

Beware of NK cells in pre-clinical metastasis models

Gene silencing of c-Met leads to brain metastasis inhibitory effects

Improved rodent models of human brain metastases

Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-2 in human lung cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer